Description du projet
Faire progresser les thérapies par lymphocytes T régulateurs
Les maladies liées à l’immunité, comme l’auto-immunité et l’inflammation chronique, sont un fardeau socio-économique important. Le traitement de ces maladies fait généralement appel à des médicaments immunosuppresseurs, alors que les lymphocytes T régulateurs ont aussi été proposés comme une thérapie prometteuse. Le projet RESHAPE, financé par l’UE, entend exploiter le rôle central que les lymphocytes T régulateurs jouent dans l’homéostasie du système immunitaire en supprimant les réponses immunitaires excessives et en maintenant la tolérance périphérique. Son objectif premier est de développer des thérapies par lymphocytes T régulateurs avancées et de démontrer leur efficacité à l’heure de rétablir l’équilibre immunologique à la suite d’un transfert adoptif clinique chez des patients souffrant de troubles immunologiques.
Objectif
Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy.
Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments.
Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation.
Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies
Champ scientifique
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
10117 Berlin
Allemagne